Literature DB >> 29101643

Dosimetric comparison of 3-dimensional conformal radiotherapy, volumetric modulated arc therapy, and helical tomotherapy for postoperative gastric cancer patients.

Cem Onal1, Yemliha Dölek2, Berna Akkuş Yıldırım2.   

Abstract

PURPOSE: To compare dosimetric data for the planning target volume (PTV) and organs at risk (OARs) between 3-dimensional conformal radiotherapy (3DCRT), volumetric modulated arc therapy (VMAT), and helical tomotherapy [1].
MATERIALS AND METHODS: The dosimetric data for 15 gastric cancer patients treated with 3DCRT, VMAT, or HT techniques were used. Cumulative dosimetric parameters, homogeneity index (HI), and conformal index (CI) were compared for the PTV and OARs.
RESULTS: The average maximum doses of PTV were significantly higher in VMAT plans than in 3DCRT (p = 0.04) and HT (p = 0.02) plans, whereas minimum dose values were significantly lower in 3DCRT plans compared with VMAT (p < 0.001) and HT (p = 0.02) plans. Liver mean dose (D mean) and D mean values for both kidneys were significantly lower in HT plans than in 3DCRT and VMAT plans. The doses in high dose regions (V30-V45) using 3DCRT plans were significantly higher compared to both VMAT and HT plans. The bowel V5-V30 and V45 was significantly less in HT plans compared to VMAT plans. There were no significant differences in dose sparing of the spinal cord.
CONCLUSIONS: The HT plans reduced the maximum dose applied to the target and improved the conformality and homogeneity of radiation, while providing sufficient PTV coverage.

Entities:  

Keywords:  Dosimetry; Gastric cancer; Helical tomotherapy; Volumetric arc therapy

Mesh:

Year:  2017        PMID: 29101643     DOI: 10.1007/s11604-017-0696-x

Source DB:  PubMed          Journal:  Jpn J Radiol        ISSN: 1867-1071            Impact factor:   2.374


  37 in total

1.  Volumetric modulated arc therapy: IMRT in a single gantry arc.

Authors:  Karl Otto
Journal:  Med Phys       Date:  2008-01       Impact factor: 4.071

Review 2.  Survival after radiotherapy in gastric cancer: systematic review and meta-analysis.

Authors:  Vincenzo Valentini; Francesco Cellini; Bruce D Minsky; Gian Carlo Mattiucci; Mario Balducci; Giuseppe D'Agostino; Elisa D'Angelo; Nicola Dinapoli; Nicola Nicolotti; Chiara Valentini; Giuseppe La Torre
Journal:  Radiother Oncol       Date:  2009-07-06       Impact factor: 6.280

3.  Development and initial validation of the medical fear survey-short version.

Authors:  Bunmi O Olatunji; Chad Ebesutani; Craig N Sawchuk; Dean McKay; Jeffrey M Lohr; Ronald A Kleinknecht
Journal:  Assessment       Date:  2011-07-29

4.  An observational study suggesting clinical benefit for adjuvant postoperative chemoradiation in a population of over 500 cases after gastric resection with D2 nodal dissection for adenocarcinoma of the stomach.

Authors:  Sung Kim; Do Hoon Lim; Jeeyun Lee; Won Ki Kang; John S MacDonald; Chan Hyung Park; Se Hoon Park; Se-Hoon Lee; Kihyun Kim; Joon Oh Park; Won Seog Kim; Chul Won Jung; Young Suk Park; Young-Hyuck Im; Tae Sung Sohn; Jae Hyung Noh; Jin Seok Heo; Yong Il Kim; Chul Keun Park; Keunchil Park
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-08-15       Impact factor: 7.038

5.  Single-arc volumetric-modulated arc therapy (sVMAT) as adjuvant treatment for gastric cancer: dosimetric comparisons with three-dimensional conformal radiotherapy (3D-CRT) and intensity-modulated radiotherapy (IMRT).

Authors:  Xin Wang; Guangjun Li; Yingjie Zhang; Sen Bai; Feng Xu; Yuquan Wei; Youling Gong
Journal:  Med Dosim       Date:  2013-06-20       Impact factor: 1.482

6.  Comparison of intensity-modulated radiotherapy and 3-dimensional conformal radiotherapy as adjuvant therapy for gastric cancer.

Authors:  A Yuriko Minn; Annie Hsu; Trang La; Pamela Kunz; George A Fisher; James M Ford; Jeffrey A Norton; Brendan Visser; Karyn A Goodman; Albert C Koong; Daniel T Chang
Journal:  Cancer       Date:  2010-08-15       Impact factor: 6.860

7.  Gastric surgical adjuvant radiotherapy consensus report: rationale and treatment implementation.

Authors:  Stephen R Smalley; Leonard Gunderson; Joel Tepper; James A Martenson; Bruce Minsky; Christopher Willett; Tyvin Rich
Journal:  Int J Radiat Oncol Biol Phys       Date:  2002-02-01       Impact factor: 7.038

Review 8.  Intensity-modulated radiotherapy for the treatment of prostate cancer: a systematic review and economic evaluation.

Authors:  S Hummel; E L Simpson; P Hemingway; M D Stevenson; A Rees
Journal:  Health Technol Assess       Date:  2010-10       Impact factor: 4.014

9.  Volumetric intensity-modulated Arc (RapidArc) therapy for primary hepatocellular carcinoma: comparison with intensity-modulated radiotherapy and 3-D conformal radiotherapy.

Authors:  Yu-Cheng Kuo; Ying-Ming Chiu; Wen-Pin Shih; Hsiao-Wei Yu; Chia-Wen Chen; Pei-Fong Wong; Wei-Chan Lin; Jeng-Jong Hwang
Journal:  Radiat Oncol       Date:  2011-06-21       Impact factor: 3.481

10.  Accelerated tomotherapy delivery with TomoEdge technique.

Authors:  Sonja Katayama; Matthias F Haefner; Angela Mohr; Kai Schubert; Dieter Oetzel; Juergen Debus; Florian Sterzing
Journal:  J Appl Clin Med Phys       Date:  2015-03-08       Impact factor: 2.102

View more
  3 in total

1.  Automated VMAT planning for postoperative adjuvant treatment of advanced gastric cancer.

Authors:  Abdul Wahab M Sharfo; Florian Stieler; Oskar Kupfer; Ben J M Heijmen; Maarten L P Dirkx; Sebastiaan Breedveld; Frederik Wenz; Frank Lohr; Judit Boda-Heggemann; Daniel Buergy
Journal:  Radiat Oncol       Date:  2018-04-23       Impact factor: 3.481

2.  miR-92b promotes gastric cancer growth by activating the DAB2IP-mediated PI3K/AKT signalling pathway.

Authors:  Qing-Feng Ni; Yan Zhang; Jia-Wei Yu; Ru-Heng Hua; Qu-Hui Wang; Jian-Wei Zhu
Journal:  Cell Prolif       Date:  2019-11-12       Impact factor: 6.831

3.  Optimal tumor coverage with different beam energies by IMRT, VMAT and TOMO: Effects on patients with proximal gastric cancer.

Authors:  Sheng-Fang Huang; Jang-Chun Lin; An-Cheng Shiau; Yun-Chih Chen; Ming-Hsien Li; Jo-Ting Tsai; Wei-Hsiu Liu
Journal:  Medicine (Baltimore)       Date:  2020-11-20       Impact factor: 1.817

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.